ELENI EFSTATHIOU to Female
This is a "connection" page, showing publications ELENI EFSTATHIOU has written about Female.
Connection Strength
0.126
-
Re-admissions for delayed complications after cytoreductive surgery and HIPEC. Acta Chir Belg. 2016 Apr; 116(2):96-100.
Score: 0.015
-
Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014; 2014:987475.
Score: 0.013
-
Peritoneal carcinomatosis 2011; it's about time for chemosurgery. J BUON. 2011 Jul-Sep; 16(3):400-8.
Score: 0.011
-
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007 Jan-Feb; 27(1B):611-7.
Score: 0.008
-
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. Urol Oncol. 2024 Sep; 42(9):291.e13-291.e25.
Score: 0.007
-
B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467.
Score: 0.005
-
Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies. Transpl Infect Dis. 2015 Apr; 17(2):201-7.
Score: 0.003
-
Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol. 2015; 2015:610597.
Score: 0.003
-
Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May; 22(5):1570-5.
Score: 0.003
-
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82.
Score: 0.003
-
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010 Oct; 24(10):1769-78.
Score: 0.003
-
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010 Jul; 85(1):1-5.
Score: 0.002
-
High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant. 2008 Mar; 41(6):547-54.
Score: 0.002
-
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol. 2007 Mar; 104(3):580-5.
Score: 0.002
-
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006 Sep 25; 6:228.
Score: 0.002
-
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006; 70(4):265-72.
Score: 0.002
-
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res. 2006 Jul-Aug; 26(4B):3175-81.
Score: 0.002
-
Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer. 2006 May-Jun; 16(3):994-9.
Score: 0.002
-
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8384-90.
Score: 0.002
-
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005 Sep-Oct; 25(5):3553-8.
Score: 0.002
-
The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol. 2005 Nov; 99(2):376-82.
Score: 0.002
-
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer. 2005 Jun 15; 103(12):2629-35.
Score: 0.002
-
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005 May; 97(2):436-41.
Score: 0.002
-
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol. 2005 Jun; 16(6):950-7.
Score: 0.002
-
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005 May; 16(5):773-9.
Score: 0.002
-
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol. 2005 Feb; 16(2):307-13.
Score: 0.002
-
Carboplatin hypersensitivity reactions: a single institution experience. J Chemother. 2005 Feb; 17(1):104-10.
Score: 0.002
-
Late relapse of epithelial ovarian cancer: a single institution experience. Eur J Gynaecol Oncol. 2005; 26(4):439-42.
Score: 0.002
-
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004 Dec; 95(3):695-700.
Score: 0.002
-
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004 Sep; 64(3):479-84.
Score: 0.002
-
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol. 2004 Aug; 15(8):1250-5.
Score: 0.002
-
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004; 5(2):112-7.
Score: 0.002
-
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004; 66(2):112-7.
Score: 0.002
-
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003 Jun; 44(6):993-6.
Score: 0.002
-
Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. Breast J. 2003 May-Jun; 9(3):260-2.
Score: 0.002
-
Extended rituximab therapy for previously untreated patients with Waldenstr?m's macroglobulinemia. Clin Lymphoma. 2002 Dec; 3(3):163-6.
Score: 0.001
-
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett. 2002 Nov 08; 185(1):61-70.
Score: 0.001
-
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol. 2002 Jun; 85(3):476-82.
Score: 0.001
-
A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicing. Cancer Genet Cytogenet. 2002 Apr 15; 134(2):175-7.
Score: 0.001
-
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology. 2002; 62(2):97-102.
Score: 0.001
-
BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat. 2000 Sep; 16(3):272-3.
Score: 0.001
-
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol. 2000 May; 17(2):106-10.
Score: 0.001